Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Infectious Disease

Surgery and Bone Involvement

At a Glance

For mycetoma, surgery is often needed for dense fungal masses, while bacterial disease usually responds to antibiotics. If infection reaches bone, limb-sparing treatment is preferred, but extensive damage may make amputation a last resort; continued medicine and follow-up help detect recurrence.

While medication is the foundation of mycetoma care, surgery plays a critical role for many patients, especially those with the fungal form of the disease (eumycetoma) [1]. Because fungal masses can be large and dense, medicine often cannot reach the center of the infection, making surgical removal necessary in many cases to achieve a cure [2][3].

The Role of Surgery in Fungal vs. Bacterial Mycetoma

Surgical decision-making is individualized. It depends on whether the infection is fungal or bacterial, but also heavily on the lesion size, location, depth, bone or joint involvement, and the feasibility of complete excision [4].

  • Eumycetoma (Fungal): Surgery is often a standard part of treatment [1]. Many experts recommend taking antifungal medication for a period of time (often 2 to 3 months) before surgery to help “shrink” the mass and make it easier to remove, though this timeline is individualized [3].
  • Actinomycetoma (Bacterial): Surgery is rarely needed [4]. These infections usually respond very well to long-term antibiotics alone [5]. Surgery is typically reserved only for rare cases that do not respond to medicine or where the infection has caused severe, localized damage [4][6].

Understanding Surgical Procedures

If your doctor recommends surgery, the goal is to remove as much of the infected tissue as possible while balancing the need to save the limb and its function [7].

  • Wide Local Excision: This is preferred for smaller, localized infections [7]. The surgeon removes the mass along with a margin of surrounding tissue. However, this margin does not always guarantee that all microscopic organisms have been removed [8].
  • Debulking: In cases where the infection is too large to remove entirely without causing major disability, the surgeon may perform “debulking” to reduce the size of the mass. This is intended to help the antifungal medication work more effectively, though it is not automatically curative [3].
  • Reconstruction: If a large area of skin or muscle is removed, you may need a skin graft or a flap (moving healthy tissue from another part of your body) to close the wound and restore function [9]. Patients should be prepared for the recovery timeline regarding anesthesia, wound care, and graft healing.

When Bone Involvement Leads to Amputation

Mycetoma is a progressive disease. If left untreated or uncontrolled, it can move from the skin into the deep fascia (connective tissue), muscles, tendons, and eventually the bone [10][11].

Once the infection reaches the bone, it can cause osteomyelitis (bone infection), creating “punched-out” holes that weaken the skeleton [12][13]. Reported rates of bone involvement vary from 10% to over 50% in different settings [14][15].

While limb-sparing surgery is always the primary goal, amputation is considered an individualized last-resort option if [7][11]:

  • The bone destruction is so extensive that the limb is functionally unsalvageable [11].
  • There is a severe secondary bacterial infection that cannot otherwise be controlled [7].
  • Multiple previous surgeries and medication cycles have failed to stop the spread [16].

The Risk of Recurrence

One of the challenging aspects of eumycetoma is the risk of recurrence—the infection coming back after it was thought to be gone [17]. Studies have shown that roughly 27% to 31% of patients in certain surgical cohorts experience a recurrence, but this rate varies greatly depending on disease extent, follow-up duration, and completeness of excision [18][17].

You may be at a higher risk for recurrence if [18][7]:

  • The infection has been present for a long time (e.g., more than 10 years).
  • The original mass was very large.
  • The infection has already reached the bone.
  • You have had previous surgeries for the same infection.

To help manage this risk, it is essential to continue taking antifungal medication after surgery for an individualized duration prescribed by your doctor [19][3]. Regular follow-up appointments and imaging are necessary to monitor for any signs of the infection returning [18].

Common questions in this guide

When is surgery needed for mycetoma?
Surgery is often part of treatment for eumycetoma because dense fungal masses can keep medicine from reaching the center of the infection. Actinomycetoma, the bacterial form, usually responds to long-term antibiotics, so surgery is generally reserved for treatment-resistant disease or severe localized damage.
How long should I take antifungal medicine before eumycetoma surgery?
Doctors often use antifungal treatment for about 2 to 3 months before surgery to help shrink the mass and make it easier to remove. The timing depends on the size, location, depth, and response of the infection, so your treatment plan may differ.
Is wide local excision different from debulking for mycetoma?
Wide local excision removes a smaller, localized mass and some surrounding tissue, with the goal of removing all visible infection. Debulking reduces the size of a larger mass when complete removal could cause major disability, so it may improve medication effectiveness but is not automatically curative.
What does bone involvement mean for mycetoma treatment?
When mycetoma reaches bone, it can cause osteomyelitis, or a bone infection, and weaken the limb. Doctors usually aim for limb-sparing treatment, but extensive bone destruction, uncontrolled secondary infection, or repeated treatment failure may make amputation a last-resort option.
How often does mycetoma come back after surgery?
Recurrence has been reported in about 27% to 31% of patients in some surgical studies, although the rate varies with disease extent, follow-up time, and how completely the infection was removed. Long-standing or large infections, bone involvement, and previous surgery can increase risk, so medication, follow-up visits, and imaging are important.
What should I expect during recovery after mycetoma surgery?
Recovery may include anesthesia recovery, wound care, healing of a skin graft or tissue flap, continued medication, and sometimes physical therapy. Arrange help with daily tasks and follow-up appointments, and ask your surgical team how to watch for infection or recurrence.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Mycetoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has the infection spread to my bone, and if so, what are the chances that medication and surgery can still save the limb?
  2. 2.For my specific type of eumycetoma, how many months of antifungal therapy do you recommend before we proceed with surgery?
  3. 3.What is the goal of my surgery—is it a 'wide local excision' to remove the entire mass, or 'debulking' to reduce the size of the infection?
  4. 4.If you find that the infection has reached my tendons or joints during surgery, how will that change the procedure?
  5. 5.What is your plan for monitoring me after surgery to catch a potential recurrence as early as possible?
  6. 6.If surgery is not successful and the infection returns, what are the next steps before we would have to consider amputation?

References

References (19)
  1. 1

    [Eumycetoma due to Fusarium chlamydosporum : Case report und review of the literature].

    Malisiewicz B, Uhrlaß S, Nenoff P, Schöfer H

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(8)):612-617 doi:10.1007/s00105-019-4430-8.

    PMID: 31289888
  2. 2

    Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.

    Fahal AH, Ahmed ES, Bakhiet SM, et al.

    The Lancet. Infectious diseases 2024; (24(11)):1254-1265 doi:10.1016/S1473-3099(24)00404-3.

    PMID: 39098321
  3. 3

    Mycetoma in north-western Yemen: Clinico-epidemiological and histopathological study.

    Khatri ML, Al Kubati SAS, Gaffer IA, Majeed SMA

    Indian journal of dermatology, venereology and leprology 2022; (88(5)):615-622.

    PMID: 35389029
  4. 4

    [Mycetoma and their treatment].

    Develoux M

    Journal de mycologie medicale 2016; (26(2)):77-85 doi:10.1016/j.mycmed.2016.03.005.

    PMID: 27260344
  5. 5

    Treatment of Madura foot: a systematic review.

    Salim AO, Mwita CC, Gwer S

    JBI database of systematic reviews and implementation reports 2018; (16(7)):1519-1536 doi:10.11124/JBISRIR-2017-003433.

    PMID: 29995713
  6. 6

    Successful Treatment of Recalcitrant Actinomycetoma of Gluteal Area with Combined Medical Treatment and Surgical Excision with Graft Reconstruction.

    Al-Kathiri L, Al-Najjar T, Al-Asmaili A

    Oman medical journal 2020; (35(2)):e111 doi:10.5001/omj.2020.29.

    PMID: 32308989
  7. 7

    Surgical management of eumycetoma: experience from Gezira Mycetoma Center, Sudan.

    Gismalla MDA, Ahmed GMA, MohamedAli MM, et al.

    Tropical medicine and health 2019; (47()):6 doi:10.1186/s41182-018-0129-2.

    PMID: 30675125
  8. 8

    The Surgical Treatment of Mycetoma.

    Suleiman SH, Wadaella el S, Fahal AH

    PLoS neglected tropical diseases 2016; (10(6)):e0004690 doi:10.1371/journal.pntd.0004690.

    PMID: 27336736
  9. 9

    Reconstructive surgery for mycetoma: Preliminary algorithm and a systematic review.

    Gismalla MDA, Bakhiet MY, Alshareef AM, et al.

    JPRAS open 2024; (40()):130-137 doi:10.1016/j.jpra.2024.02.002.

    PMID: 38854620
  10. 10

    Mycetoma: The Spectrum of Clinical Presentation.

    Fahal AH, Suliman SH, Hay R

    Tropical medicine and infectious disease 2018; (3(3)) doi:10.3390/tropicalmed3030097.

    PMID: 30274493
  11. 11

    Advanced Eumycetoma of the Right Foot Resulting in Below-Knee Amputation in Somalia: A Case Report.

    Mahamud MA, Ahmed MM, Hassan SA, et al.

    International medical case reports journal 2026; (19()):633948 doi:10.2147/IMCRJ.S633948.

    PMID: 42808000
  12. 12

    Mycetoma imaging: the best practice.

    Bahar ME, Bakheet OELH, Fahal AH

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2021; (115(4)):387-396 doi:10.1093/trstmh/traa178.

    PMID: 33537774
  13. 13

    The importance of diagnostic imaging of mycetoma in the foot.

    Guerra-Leal JD, Medrano-Danés LA, Montemayor-Martinez A, et al.

    International journal of dermatology 2019; (58(5)):600-604 doi:10.1111/ijd.14351.

    PMID: 30565209
  14. 14

    Mycetoma in Uganda: A neglected tropical disease.

    Kwizera R, Bongomin F, Meya DB, et al.

    PLoS neglected tropical diseases 2020; (14(4)):e0008240 doi:10.1371/journal.pntd.0008240.

    PMID: 32348300
  15. 15

    A study of 87 mycetoma patients seen at three health facilities in Nouakchott, Mauritania.

    Kébé M, Ba O, Mohamed Abderahmane MA, et al.

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2021; (115(4)):315-319 doi:10.1093/trstmh/traa197.

    PMID: 33580966
  16. 16

    Primary mycetoma of the calcaneum: Case report on an unusual hazard of barefoot walking.

    Nasir MU, Mukhtar MU, Nasir Z, et al.

    International journal of surgery case reports 2023; (108()):108418 doi:10.1016/j.ijscr.2023.108418.

    PMID: 37343500
  17. 17

    Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan.

    Fahal A, Mahgoub el S, El Hassan AM, Abdel-Rahman ME

    PLoS neglected tropical diseases 2015; (9(3)):e0003679 doi:10.1371/journal.pntd.0003679.

    PMID: 25816316
  18. 18

    Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience.

    Wadal A, Elhassan TA, Zein HA, et al.

    PLoS neglected tropical diseases 2016; (10(10)):e0005007 doi:10.1371/journal.pntd.0005007.

    PMID: 27798643
  19. 19

    Mycetoma management and clinical outcomes: the Mycetoma Research Center experience.

    Musa EA, Abdoon IH, Bakhiet SM, et al.

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2023; (117(1)):12-21 doi:10.1093/trstmh/trac069.

    PMID: 35903002

This page is for informational purposes only and does not constitute medical advice. Your infectious disease and surgical teams can assess bone involvement, limb function, and recurrence risk to recommend the safest mycetoma treatment for you.